Quantcast

Latest Chemotherapy regimens Stories

2009-07-15 09:05:21

U.S. medical scientists say they have developed a new chemotherapy regimen for pediatric Hodgkin's lymphoma patients. Dr. Cindy Schwartz of Brown University Medical School's Hasbro Children's Hospital said the new treatment enhances efficacy through dose-dense drug delivery, while simultaneously reducing the long-term risks presented by high cumulative dose chemotherapy. Schwartz said current therapy for the disease in the United States did not include the most modern treatment models, in...

2009-06-01 07:00:00

MALVERN, Pa., June 1 /PRNewswire/ -- Ascenta Therapeutics announced today that promising results from ongoing clinical studies in prostate, brain and lung cancers were among the data presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. (Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) "We are delighted with the depth and breadth of the data available on our lead...

2009-05-19 10:00:00

Updated Safety data presented at BIO International Convention in Atlanta ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs are typically not to be used due to the increased risk of cardiac failure. As noted...

2009-03-13 16:21:00

NCCN presented new NCCN Clinical Practice Guidelines in Oncology(TM) for Primary Cutaneous B-Cell Lymphoma as well as important updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas at the NCCN 14th Annual Conference. The new NCCN Guidelines were written to distinguish Primary B-Cell Lymphomas from their nodal counterparts and provide clinicians with treatment recommendations. Andrew D. Zelenetz, MD, PhD, and Steven M. Horowitz, MD, both of Memorial Sloan-Kettering Cancer Center,...

2009-01-14 07:00:00

- Incremental Data to be Presented at ASCO GI Symposia Continue to Support Picoplatin as Neuropathy-Sparing Alternative to Oxaliplatin in First-Line Colorectal Cancer Treatment - SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with...

2009-01-13 06:45:00

Innovative Therapy Ensures Greater Patient Compliance, Improves Quality of Life MOUNTAIN VIEW, Calif., Jan. 13 /PRNewswire/ -- Based on its recent analysis of the biopharmaceuticals market, Frost & Sullivan recognizes Neotropix, Inc. with the 2009 U.S. Frost & Sullivan Award for Product Innovation of the Year. This award acknowledges the company's introduction of the innovative virotherapy NTX-010 (Seneca Valley Virus), an oncolytic picorna virus for treating small cell lung cancer...

2008-12-08 16:46:00

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results from two large, multi-center, randomized Phase III clinical trials of VELCADE based combinations for the induction treatment of transplant-eligible patients with previously untreated multiple myeloma (MM). Prolonged progression-free survival (PFS) was observed in one study comparing VELCADE and dexamethasone (VcD) with vincristine, adriamycin and dexamethasone (VAD), as well as in...

2008-11-12 12:00:00

Given that patients with relapsed aggressive non-Hodgkin's lymphoma are poorly served by current therapies, a significant unmet need exists in this setting. Having achieved positive results in a Phase III trial, pixantrone has the potential to overcome regulatory hurdles and take advantage of the low barriers to entry in the third-line treatment of relapsed aggressive NHL. The EXTEND Phase III trial involved 140 patients who had relapsed aggressive NHL and had not responded to two previous...

2008-11-03 03:00:04

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has closed the data set for preliminary analysis of the primary endpoint in the phase III EXTEND (PIX301) trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and it has provided Novartis notice that the data set has been closed. The primary endpoint for the study is the complete remission (CR) and unconfirmed complete...

2008-09-15 21:00:09

By Eric Eyre For years, cancer patients have complained about the memory loss and attention problems they experience while undergoing chemotherapy. A new animal study from West Virginia University's School of Medicine suggests there may be a way to prevent those memory- related side effects - often called "chemo-brain." WVU researchers have discovered that injections of a powerful antioxidant called N-acetyl cysteine, or NAC, could stop memory loss caused by chemotherapy drugs,...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related